BioVie Inc Dossier - Source-backed chat

BioVie Inc

BIVINASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.78

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.47Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $12.8M

Enterprise Value $3.8M

Shares Outstanding 8.5M diluted

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

BioVie Inc. is a high-risk, high-reward clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases and advanced liver disease. The investment thesis centers on its lead asset, bezisterim (NE3107), which targets neuroinflammation and insulin resistance—two key drivers of Parkinson's and Alzheimer's diseases. With two major Phase 2 clinical readouts expected in Q3 2026 (SUNRISE-PD in early-stage Parkinson's and ADDRESS-LC in Long COVID), the company is approaching significant near-term catalysts that could dramatically re-rate its valuation. While the company faces going concern risks and potential dilution from its recently filed $300 million shelf registration, positive clinical data would validate its novel anti-inflammatory mechanism and position it for lucrative licensing or co-development partnerships.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$5.26

High · most bullish analyst$5.51

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case occurs if both Phase 2 trials fail to meet their primary endpoints or show unfavorable safety profiles, or if the company is forced to execute highly dilutive equity raises under its $300 million shelf registration at depressed share prices. Failure of bezisterim would leave the company with limited pipeline options and severely constrained capital, threatening its viability as a going concern.

Base CaseCentral scenario

The base case assumes that bezisterim demonstrates positive trends in motor and non-motor symptom improvements in the SUNRISE-PD trial and shows efficacy in reducing neurocognitive symptoms in the ADDRESS-LC trial. This clinical validation would significantly de-risk the asset, driving institutional interest and potentially facilitating a strategic partnership or licensing deal to fund larger Phase 3 trials, mitigating near-term dilution concerns.

Bull CaseUpside scenario

Positive Phase 2 readouts for bezisterim in Parkinson's (SUNRISE-PD) and Long COVID (ADDRESS-LC) in Q3 2026 validate its novel anti-inflammatory mechanism, de-risking the pipeline and attracting lucrative strategic partnerships or non-dilutive funding.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Novel mechanism of action targeting both neuroinflammation and insulin resistance without immunosuppression.
Two major near-term clinical catalysts in Q3 2026 (SUNRISE-PD and ADDRESS-LC topline data).
ADDRESS-LC trial is fully funded by a $13.13 million grant from the U.S. Department of War, preserving internal cash.
Significant valuation upside from a depressed market capitalization relative to the multi-billion dollar addressable markets in Parkinson's, Alzheimer's, and Long COVID.

Key Investment Risks

High clinical development risk inherent to neurodegenerative disease therapeutics.
Limited cash runway and going concern risk, requiring future capital raises that may dilute existing shareholders.
History of clinical trial complications, such as the protocol and GCP violations in the previous Phase 3 Alzheimer's trial.
High stock price volatility typical of micro-cap clinical-stage biotechnology companies.

Thesis Invalidation Triggers

Failure of bezisterim to show clinical efficacy or acceptable safety in the SUNRISE-PD or ADDRESS-LC trials.
Inability to secure strategic partnerships or additional financing, leading to insolvency or severe operational curtailment.
Regulatory actions or clinical holds imposed by the FDA on the bezisterim or BIV201 development programs.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.